en faisant une recherche nicox sur leur site ( ça coûte : £8,992.00 )
il y avait ceci :
Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population (Datamonitor)
Market: Healthcare and Medical
Published Date: 04/12/2009
Report Title: Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population
Table of Contents: View Table of Contents
Report Type: Market Report
Number of Pages: 205
The report expects osteoarthritis prevalence to grow by over 10 million by 2020, owing mainly to an aging population. In the near-term the approach to treatment will remain constant, with improved side-effects dominating the unmet needs. However, therapies which target the underlying causes of osteoarthritis have the potential to reshape osteoarthritis treatment.
*Snapshot of the osteoarthritis market based on a survey of 180 rheumatologists/primary care physicians, with views from key opinion leader interviews
*Analysis of osteoarthritis epidemiology, with future projections of prevalence and patient numbers to 2020
*Overview of treatment options at the class and molecule level, as well as treatment outcome analysis
*Assessment of treatment satisfaction, unmet needs and physicians' awareness of key pipeline therapies
The estimated diagnosis rate of 55% reflects a lack of treatment-seeking by mild sufferers of the disease, who often resort to self-medication. This equates to nearly 37 million undiagnosed patients in 2009 and with a predicted rise in osteoarthritis numbers this is a market with growth potential.
Pain-relieving drugs, particularly, oral non-steroidal anti-inflammatory drugs (NSAIDs) are the foundation of pharmacological therapy in osteoarthritis. Physicians continue to be concerned over NSAID toxicity, with three-quarters of severe patients who are receiving NSAIDs currently co-prescribed a gastroprotectant.
Physicians are generally unsatisfied with current osteoarthritis pharmacological treatments. A clear need for alternative drugs exists to treat this prevalent condition. 41% of physicians ranked disease modifying osteoarthritis drugs (DMOADs) as the highest unmet need, but the majority of physicians estimate that DMOADs are 8 years from the market.
Reasons to Purchase
*Understand current therapy trends for the major drug classes used in osteoarthritis split by disease severity and assess unmet needs in the disease
*Validate new product forecasting based on diagnosis rates and treatment by patient segmentation and drug class
*Use the interactive Excel model of treatment trees and patient numbers to estimate the osteoarthritis population in each of the seven major markets